This website uses cookies. By clicking Accept, you consent to the use of cookies. Click Here to learn more about how we use cookies.
Accept
Reject
Help

Upcoming Webinars

cancel
Turn on suggestions
Auto-suggest helps you quickly narrow down your search results by suggesting possible matches as you type.
Showing results for 
Search instead for 
Did you mean: 

Upcoming Webinars
Leveraging Novel Modalities for Oncology Therapies
Wednesday, October 26, 2022
Register
Over the last two decades, traditional small molecules and antibody drugs have provided tremendous benefits to cancer patients. Due to the complexity of the disease, incomplete response and drug resistance ultimately emerge. New modalities beyond traditional small molecules and antibodies can provide unprecedented opportunities for drugs previously deemed “undruggable” targets. As an example, KRASG12C covalent inhibitors have shown promise for the treatment of Non-small cell lung cancer with KRASG12C mutations. Other KRAS mutants which cannot be inhibited by covalent inhibitors remain “undruggable”. In this webinar, we will discuss the opportunity of new modalities like oligonucleotides and TCR-engineered T cell therapy for treating KRAS mutant cancers, as well as various modality toolboxes to support drug discovery programs.     Key Learning Objectives: Review and highlight the use of various drug modalities in oncology  Dive into specific examples of different modalities for a particular target and learn key takeaways  Who Should Attend: Scientists (biologist, oncologist, chemist, etc.)  Program leaders and strategists  Project managers  Medical doctors  Individuals interested in understanding how a new modalities could expand therapies  Brought to you by: Werngard Czechtizky Executive Director Head Medicinal Chemistry, Chair of AZ Global Chemistry Leadership, Astrazeneca Luping Lin Director Biology, WuXi AppTec Jiafeng Rui Associate Director, Biology, WuXi AppTec Melissa O'Meara Forensic Science Consultant, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Picking Winners: Using Computational Tools to Shorten the Drug Discovery Cycle Time
Thursday, October 27, 2022
Register
Computational methods can significantly shorten the drug discovery process, accelerating the identification of hit compounds against a therapeutic target and the progression into promising pre-clinical candidates. When used effectively, computational approaches help predicting the molecules that are most likely to succeed, preventing unnecessary wet chemistry and saving time, money, and resources.    In this webinar, we will show how computational tools help research chemists discover and optimize novel small molecules more efficiently and effectively through the synergistic application of ligand-based and structure-based methods. These include cutting-edge methods such as Free Energy Perturbation (FEP) for accurately predicting the biological activity of new compounds before synthesis, and tools for understanding the structure-activity relationships of ligand series to inform new molecule design.    Key Learning Objectives: Understand how to synergistically apply different computational methods to analyze the information available in a drug discovery project, obtaining valuable information on what to do next.  Learn the benefits and limitations of different methods for predicting the activity of new compounds and find the best molecules to progress.  Who Should Attend: Computational chemists  Medicinal and synthetic chemists  Drug discovery scientists in academia  Drug discovery scientists in biotechnology, pharmaceutical, agrochemical, flavor and fragrance industry  Brought to you by: Giovanna Tedesco Head of Products, Cresset Ann Thayer Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Addressing Sustainability Challenges with Earth Abundant Metal Catalysis
Thursday, October 27, 2022
Register
How chemists interact with and ultimately use the elements on the periodic table is one of the primary sustainability challenges for the 21st century. Applications ranging from alternative energy to the synthesis of pharmaceuticals and every day products should rely on terrestrially abundant elements such as iron rather than rare ones that have a large environmental footprint associated with mining and purification.   Join Paul Chirik, Edward S. Sanford Professor at Princeton University and Editor-in-Chief of Organometallics as he explores the new chemistry enabled by catalysis with Earth abundant transition metals. Dr. Chirik and his research group strive to discover highly effective catalysts with applications in the pharmaceutical, flavor and fragrance, silicones, energy and polymer science industries and often engage with industrial collaborators. They seek to uncover the unique pathways that enable these transformations, many of which are distinct from precious metals and rely on the unique electronic structures of the first row transition metals. Register now to discover the distinct chemistry enabled by iron and cobalt catalysts and the design principles that were used in catalyst discovery. Learn about real-life applications and broad challenges that confront the field such as air-stable, easily handled precursors, functional group tolerance, ligand design and understanding reaction mechanism.   This ACS Webinar is moderated by Director of Sustainable Development Adelina Voutchkova-Kostal of ACS and is co-produced with the ACS Office of Sustainable Development and Organometallics.
2022-09-15-stock-600-400px-acsnetwork.jpg
Labels (1)
Labels
Event has ended
Peace-of-Mind with Secure Data Management
Tuesday, November 1, 2022
Register
Over the last two and a half years, we’ve all had to learn to communicate and work in new ways. With the help of technology, we’ve connected with colleagues across the globe in ways we never thought possible.  The ability to work remotely has ensured continued quality management of products consumed daily. For an analytical chemist or lab manager, quality management may include reviewing and approving data from the safety of your office whether in the lab or at home. No matter where the data is reviewed, completeness, accuracy and traceability must be maintained. This can be accomplished with a secure and efficient software platform.    During this webinar, Kerri-Ann Blake, Product Manager for Titration, and Daniel Schmidt, IT Systems Engineer, will introduce you to the OMNIS data management platform. They will discuss how you can securely implement the software, review and sign data. You’ll learn how to track it all via audit trail from anywhere in the world - giving you peace-of-mind that all your data is being kept safe.    Key Learning Objectives: Introduce OMNIS software’s seamless networking capability and user management system  Demonstrate convenient audit trail features with next level compliance and data integrity  Discuss system security and ease of implementation  Who Should Attend: QC/QA, R&D and Process Development Lab Managers and Users  Anyone performing titrations in a 21 CFR Part 11 Compliant Environment  Those interested in data security and integrity  Brought to you by: Kerri-Ann Blake Titration Product Manager Metrohm USA Daniel Schmidt IT Systems Engineer Metrohm USA Catherine Dold Health & Environment Writer C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Data-Driven R&D in Chemicals & Materials: Why an Open Platform is Essential
Wednesday, November 2, 2022
Register
Dotmatics vision is that scientific applications that operate on top of a unified and data-centric platform allow for unparalleled insights. In this webinar we explore what this means in the context of chemicals and materials R&D. Particular focus will be on workflow complexity, variability in data types, and the breath of scientific disciplines such a platform needs to support.    With this unparalleled access to research data, scientists are in a much stronger position to tackle today’s mega challenges including sustainability, energy, food supply, etc. We see this as a strong driver as to why organizations are investing in their data infrastructure, and we will provide examples of some of our most recent efforts in this area.    Key Learning Objectives: An open scientific platform provides unified access to data  Existing R&D IT systems can be left in-place while allowing for full data interoperability  Unified access to data is foundational for data-driven R&D, data modelling initiatives or any organization that desires to use their data more strategically  Who Should Attend: R&D managers, directors, VP of R&D  Laboratory managers  R&D IT professionals  Lead scientists in materials science, chemical industry, energy, CPG  Brought to you by: Max Petersen Associate VP of Chemicals & Materials Marketing, Dotmatics Melissa O'Meara Forensic Science Consultant, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Accelerate your Chemical Research with the Help of Modern Tools
Thursday, November 3, 2022
Register
In an ideal world, most of a chemists’ time would be spent purely on solving complex scientific problems, performing chemistry at the bench, and changing the world one molecule at a time. However, the day-to-day reality involves many more trivial and time-consuming tasks related to their work, including drawing molecules, schemes, and reporting on the work they have done. But what if there was another way?   Join Lindsey Rickershauser, ChemDraw Product Manager, and Pierre Morieux, a.k.a ChemDraw Wizard, to learn about the newest capabilities that will empower you to create visually compelling beautiful chemical drawings more efficiently, easily depict your research whether you are working on small molecule or peptide/nucleotide chemistry and expedite mundane tasks such as managing molecules and reactions as well as everyday reporting.   Key Learning Objectives: Join us to learn how powerful capabilities in the latest v22 release of ChemDraw and ChemOffice can dramatically increase your productivity and accelerate your research by enabling you to:   Transform the way your chemistry presentations look with beautiful native colored 3D renderings of your molecules Quickly and easily represent and share complex natural and unnatural biopolymer and oligonucleotide sequences Improve the efficiency of your research by drawing entire complex reactions schemes in minutes with new hotkeys and improved shortcuts. Who Should Attend: Chemists Peptide Chemists Oligonucleotide Chemists Research Chemists Organic Chemists Inorganic Chemists Organometallic Chemists Polymer Chemists Ph.D. Students and Post-Docs Patent Attorneys Brought to you by: Lindsey Rickershauser, Ph.D. ChemDraw Product Manager, PerkinElmer Informatics Pierre Morieux, Ph.D. Chemistry Product Marketing Manager, ChemDraw Wizard, PerkinElmer Informatics Melissa O'Meara Forensic Science Consultant, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Highlights from the New ICH Global Guideline on Drug Interaction Studies
Tuesday, November 8, 2022
Register
In June 2022, the ICH released the first draft of its harmonized Drug Interaction Studies Guideline (M12). The guideline is the result of several meetings of the Expert Working Group since 2018 with the goal of harmonizing member regulatory agencies’ guidelines to create a single guideline that will be used across all member countries.     Join us to hear drug-drug interaction (DDI) experts, Drs. Brian Ogilvie and Maciej Czerwinski, discuss the differences between current in vitro DDI guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan drug development strategies to meet the ICH M12 guideline.    Key Learning Objectives: An understanding of the development impacts of the new ICH Drug Interaction Studies Guideline. Differences with current FDA, EMA and PMDA DDI guidance documents.  How to plan drug development strategies to meet the ICH M12 guideline.  Who Should Attend: Research scientists and drug development leadership aiming for successful IND / NDA submission, needing to meet regulatory requests and expectations, desiring to formulate a development plan that mitigates risks of late stage failure, or simply wanting to better understand the ADME properties and potential DDI risks of their compound.  Brought to you by:   Brian Ogilvie, Ph.D Vice President of Scientific Consulting XenoTech Maciej Czerwinski, Ph.D. Director of Scientific Consulting XenoTech Jeff Huber Contributing Editor C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Unlocking the Benefits of AI for Research and Product Development
Wednesday, November 9, 2022
Register
While there’s no denying that artificial intelligence has become the latest buzzword in product development, the hype exists for a reason.    With AI, organizations could:  Develop their understanding of the cause-and-effect relationships between ingredients and technical or functional performance  Facilitate assessments of material compatibility and manufacturability  Speed up new and derivative product development    But what do applied science companies need to do to realize the promise of AI? What stands in the way of wider adoption? And how will it actually help their lab teams drive better research and product development outcomes?    If you’re working on AI — or if you’re interested in learning more about what it takes to transition your R&D to an AI-ready data management structure — you won’t want to miss this webinar.    Key Learning Objectives: The reasons why artificial intelligence is a game changer for research and product development The factors that make it so hard to actualize Why lab data capture infrastructure is critical to achieving positive outcomes through AI How to start, and ultimately scale, your AI initiative Who Should Attend: Laboratory Managers Technical Directors Product Development Leaders Research and Innovation Leaders IT Leaders Brought to you by: Sasha Novakovich Co-founder and CEO, Alchemy Cloud, Inc. Catherine Dold Health & Environment Writer, C&EN Media Group
%7B54ef2d80-b679-4723-b72f-5a341c0dbce2%7D_Final_banner_image_Alchemy_AI_webinar
Labels (2)
Labels
Event has ended
Analysis of Trace Impurities in Hydrogen by Gas Chromatography
Thursday, November 10, 2022
Register
Hydrogen (H2) is the simplest and most abundant element in the universe. Since, it only occurs naturally on Earth when combined with other elements it must be produced from other sources. It can be produced without a carbon footprint from variety of sources, including natural gas, coal, biomass, waste materials, or by splitting water molecules. Hydrogen fuel consumption is not currently widespread, but there has been a growing interest in its use as a potential energy source across the economy. As hydrogen is increasingly adopted, strict requirements have been imposed to limit pollution from any impurities in the gas. Specifications for the purity of hydrogen used in other applications are also becoming more stringent. Hydrogen is used in the manufacturing and processing of large-scale integrated circuits (ICs), smelting and processing of high-purity metals, development and production of liquid hydrogen and its derivative products. In this presentation we will discuss Agilent’s current gas chromatography solutions to analyzing trace level impurities in hydrogen.    In this webinar we will discuss the gas chromatography and how it is used to analyze trace impurities in hydrogen gas. We will review what impurities are important to hydrogen analysis and we will discuss the different techniques used to accomplish these analyses. We will cover basic chromatography concepts along with specialized detectors such as PDHID, FID, TCD, MSD, SCD, and NCD.    Key Learning Objectives: Learn why hydrogen analysis is important.  Learn which impurities are important in hydrogen analysis.  Learn techniques necessary to analyze these impurities. Who Should Attend: Laboratory managers  Chromatographers  New product developers  Brought to you by: Shannon Coleman GC Application Scientist, Agilent Technologies Catherine Dold Health & Environment Writer, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Unveiling Solubility, Dissolution and Permeability In Vitro: How GSK Sees the (UV) Light
Thursday, November 17, 2022
Register
Selection of the correct molecule and an understanding of its behavior in-vivo and any potential risks to progression are critical in the development of new medicines. Frequently pharmaceutical scientists are asked to make more decisions earlier in the development process and with less material.    Historically, the measurement of dissolution rate to assess the properties of an Active Pharmaceutical Ingredient (API) has been performed at later stages of development for quality control purposes rather than to select molecules or determine possible performance risks. This approach typically uses large amounts of material and does not provide a fundamental or mechanistic understanding on the behavior of the material or highlight its potential failure modes, and in many cases provide little correlation to changes that could potentially occur in vivo.    GSK will discuss how it uses a suite of tools, including Pion’s range of fiber optic dissolution and UV imaging techniques, to aid the characterization of API’s to improve molecule selection and help identify differences due to changes in various physChem properties.    Key Learning Objectives: Solubility and dissolution assessment and characterization at different phases of pharmaceutical development. Novel dissolution methodologies to support molecule and formulation approaches for new chemical entities. Determination of risk analysis for changing product performance due to the presence of different polymorphic forms, versions or non-robust formulations. Learn from case studies using UV dissolution data to select, characterize or troubleshoot real molecules currently in research and development, and how this data correlated or supported more traditional pharmaceutical analysis tests such as USP II dissolution.  Who Should Attend: Pharmaceutical analysts, laboratory technicians and formulation scientists (Industrial Pharmacists), anyone interested in the use of novel dissolution tools to help support molecule and drug product development. Brought to you by: Speakers: Wayne Matthews Principal Investigator R&D, Drug Substance Development, Materials Science UK Catherine Dold Health & Environment Writer C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Introduction into Fragment Based Drug Discovery
Tuesday, November 29, 2022
Register
Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification in the drug discovery process. Fragments are small molecules with a low molecular weight, smaller than lead molecules or druglike molecules. The FBDD technology is based on identifying small chemical fragments, which bind to the biological target and which are then optimized into leadlike and druglike molecules. In contrast to high throughput screening (HTS) where libraries of millions of compounds with molecular weights of around 500 Da are tested and nanomolar binding affinities are found, fragments come from much smaller libraries and show weaker binding affinities. They still make good starting points for drug discovery.    In contrast to hit identification by HTS the conditions for FBDD are different. A smaller fragment library, fragment hits with weaker affinities, the need for guidance by structure information and the use of compound metrics in the optimization are central elements of FBDD. The webinar will give insight into this technology and will show how FBDD can be successfully applied for the identification of novel and potent lead compounds   Key Learning Objectives: Basics of how the FBDD works  How FBDD can be successfully applied Well established assays for FBDD  Who Should Attend: Senior project managers of drug discovery/R&D  Senior directors of drug discovery/R&D  Senior scientists of drug discovery/R&D, including senior medicinal chemist, senior biology/protein science scientist, etc. Drug discovery researchers (Professors/PIs from academy)  Brought to you by: Speakers: Moran Jerabek-Willemsen, PhD Head of Biophysics & Screening, WuXi AppTec HitS Andreas Schoop, PhD Head of Medicinal Chemistry, WuXi AppTec HitS Jeff Huber Contributing Editor, C&EN Media Group
%7Bdc2f6c8f-a243-4d75-8c84-a028deafdea7%7D_thumbnail_Banner_Image_%281200x630%29
Labels (2)
Labels
Event has ended
AI-Driven Product Development: Characteristics of Success
Wednesday, November 30, 2022
Register
Artificial intelligence is often described as "the future" of product development, but this is just the beginning. The world's most agile and innovative materials and chemicals companies are currently deploying this technology today to:    • Accelerate the development and deployment of sustainable, high-performing products    • Respond to a changing supply chain and regulatory landscape    • Improve customer responsiveness    Our industry is changing - it is not hype. Are you and your organization ready to use digital and AI-based tools to drive product, operational, and technical excellence?    In this webinar, you'll learn about the characteristics of success and key takeaways from Citrine Informatics 8+ years of helping customers in the materials and chemicals industry apply AI to product development challenges.    Key Learning Objectives: How materials and chemicals companies are using AI today to accelerate product development.  The characteristics that have led to commercial success of AI-driven product development.  Key considerations for applying AI to R&D.  Who Should Attend: Executives and business leaders   Product developers and researchers  R&D and innovation leaders  Lab managers  Engineers, chemists, and materials scientists  Brought to you by: Speakers: Josh Tappan Director of Marketing, Citrine Informatics Dr. Jacob Mohin Senior Data Solutions Engineer, Citrine Informatics Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7B96b2a479-b938-4ae0-bd1c-010e62d6f34e%7D_CitrineBanner_Image_CEN_11_30_2022
Labels (2)
Labels
Event has ended
Discovery and Characterization of Oligonucleotide Therapeutics
Thursday, December 1, 2022
Register
Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. This webinar will present recent developments in oligonucleotide chemistry, biology, and DMPK.     Our speaker panel of experts are involved in providing state of the art technical support to the discovery stages of an oligonucleotide therapeutic program. They will review the synthesis and modification of oligonucleotides, design and execution of suitable in vitro and in vivo assays, and methods for determining pharmacokinetic parameters. Finally, our expert panel will be available for a question-and-answer session.    Key Learning Objectives: Examine the synthesis and modification of oligonucleotides  Explore methods for determining pharmacokinetic parameters Hear about state-of-the-art discovery strategies Who Should Attend: Professionals working in the following areas of oligonucleotide science: Drug Discovery, Preclinical, RNA Biology/Discovery, Novel Therapeutic Modalities    Brought to you by:   Speakers: Dave Madge Vice President, WuXi AppTec Qiong Zhou Executive Director, Discovery Biology, WuXi AppTec Jun Zhou Senior Principal Scientist, Associate Director, WuXi AppTec Nan Zhao Principle Scientist III, DMPK Service Department, WuXi AppTec Catherine Dold Health & Environment Writer, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
New Advancements in Preparing Solid and Semi-Solid Samples for POPs Analysis
Wednesday, December 7, 2022
Register
Accelerated solvent extraction is a high-temperature and high-pressure extraction technique that is widely used in environmental, chemical, and food analysis. Discover a truly new technology that has pushed accelerated solvent extraction to the next level. For the first time, a true walkaway, sample-to-vial system is available which brings tremendous improvements to processing solid and semi-solid samples for POPs analysis, making the lab more productive and reducing costs.     In this presentation, we discuss a new parallel extraction protocol for pursuing extractions in gas-assisted extraction mode followed by quantitation for persistent organic pollutants (POPs). We present here performance data of the new method for analyte extraction and evaporation in the same platform from soil samples for different POPs (dioxins, furans, and PCBs). Unlike traditional methods such as liquid-solvent extraction followed by N2 stream evaporation, the fully automated solvent extraction and evaporation system saves time, solvent, and labor, while ensuring high reproducibility and productivity for analytical testing.    Key Learning Objectives: Improve your sample preparation process with a more efficient way of extracting organic compounds from solid samples     Discover a true, walk-away sample to vial workflow which will allow you and your team to accomplish more important tasks in your lab.    See how combining and automating the extraction and evaporation process while processing 4 samples in parallel provides you with better efficiency and productivity   Who Should Attend: Lab managers/Lab directors  Lab technicians  Academic researchers  Research scientists/chemists  Brought to you by: Speakers: Chris Shevlin Scientific and Educational Affairs Manager, Ion Chromatography and Sample Preparation, Thermo Fisher Scientific Matthew MacLennan Senior Scientist and Director, LC/MS/MS DevOps, Pacific Rim Labs Catherine Dold Health & Environment Writer, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Event has ended
Polymer Characterization Using Field-Flow Fractionation Combined with Multi-Angle Light Scattering
Thursday, December 8, 2022
Register
TFFFC (Toulouse FFF Center) is a platform dedicated exclusively to field-flow fractionation (FFF) techniques used to characterize macromolecules and nanoparticles. It contains four asymmetrical-flow FFF (AF4) systems—including 2D systems—with an electrical AF4 (EAF4) module, a sedimental FFF system, a thermal FFF system, and a capillary electrophoresis system. The platform supports industries and public labs working on agri-food, cosmetic, pharmaceutical, chemistry, and environmental sciences.    In this webinar, we will discuss three recent case studies employing FFF:    •  Characterization of polyoxazoline nano-vectors for photodynamic therapy     •  A study of the structural conformation of enzymatic cross-linked caseins particles in neutral and acidic conditions    •  Analysis of ultra-high molar mass polyacrylamides used for oil extraction     Key Learning Objectives: Introduction to FFF-MALS  The capabilities of FFF techniques  What TFFFC platform provides for biophysical characterization  Who Should Attend: All scientists interested in detailed characterization of synthetic and natural polymers using FFF-MALS  Brought to you by: Speakers: Frédéric Violleau Dean of Research, Ecole d’Ingénieurs de Purpan Marie Hennetier TFFFC Platform Manager, Ecole d’Ingénieurs de Purpan Lionel Rouzic Application Engineer, Wyatt Technology, France Catherine Dold Health & Environment Writer, C&EN Media Group
%7Ba0262243-bbd5-4d84-94aa-d4ed21f3a31b%7D_wyattbannerimage
Labels (2)
Labels
Event has ended
View:

From Food Chemistry to Career Advice to the latest on COVID-19 Vaccines, ACS Members with the Premium Package have exclusive access to the entire library of ACS Webinars® recordings.

Explore the Library

Stay up to date with the latest scientific research, applications and technology. Recordings of C&EN Webinars are available to the general public for 1 year after broadcast.

Explore the Library